Avadel Pharmaceuticals Plc (AVDL) - News Archive

Avadel Pharmaceuticals Attracts Talent with Inducement Awards: What It Means for ShareholdersIn a strategic move to bolster its workforce, Avadel Pharmaceuticals plc (Nasdaq: AVDL) recently announced the grant of nonsta...

Avadel Pharmaceuticals Seeks Revival Amid Financial Struggles: New VP of Sales and Inducement Awards Signal Shift in Strategy DUBLIN, Feb. 24, 2025 – In a swift response to financial pressures, Avadel Pharmaceuticals pl...

Avadel Pharmaceuticals Announces Inducement Awards Amidst Ongoing DevelopmentsIn an effort to attract top-tier talent and drive continued growth, Avadel Pharmaceuticals plc (Nasdaq: AVDL) recently announced the approval...

An Examination of the Efficacy of LUMRYZ Extended-Release Oral Suspension in Ameliorating Symptoms of Narcolepsy: A PerspectiveEsteemed Scholars and Practitioners of the Pharmaceutical Arts,It is with great anticipation...

Rise and Shine: Impact of Once-Nightly LUMRYZ on Narcoleptic Patient Preference and Avadel Pharmaceuticals In the relentless pursuit of alleviating the burdens of narcolepsy, Avadel Pharmaceuticals has forged a signific...

In the year of Our Lord, Two Thousand and Twenty-Four, as the march of medical science continues to unfold, it is with great fervour that we report developments in the field of pharmacotherapy for individuals afflicted...

Idiopathic hypersomnia (IH) is a chronic sleep disorder characterized by excessive daytime sleepiness, prolonged nighttime sleep, and difficulty awakening after sleep. This condition significantly impairs an individual’...

At the prestigious SLEEP 2024 Conference, Avadel Pharmaceuticals unveiled compelling new insights related to their flagship extended-release oral suspension drug, LUMRYZ (sodium oxybate). This year, an impressive 11 acc...